Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?

Full text
Author(s):
Show less -
Nani, V, Joao ; Dal Mas, Caroline [1] ; Yonamine, Camila M. [1] ; Ota, Vanessa K. [2] ; Noto, Cristiano [3, 4] ; Belangero, I, Sintia ; Mari, Jair J. [3] ; Bressan, Rodrigo [3] ; Cordeiro, Quirino [4] ; Gadelha, Ary [3] ; Hayashi, Mirian A. F. [1, 5]
Total Authors: 11
Affiliation:
[1] Nani, Joao, V, Univ Fed Sao Paulo UNIFESP, Dept Pharmacol, Sao Paulo - Brazil
[2] I, Univ Fed Sao Paulo UNIFESP, Dept Genet, Sao Paulo - Brazil
[3] Nani, Joao, V, Univ Fed Sao Paulo UNIFESP, Dept Psychiat, Sao Paulo - Brazil
[4] Univ Fed Sao Paulo UNIFESP, First Episode Psychosis Program, Sao Paulo - Brazil
[5] Nani, Joao, V, CNPq, Natl Inst Translat Med INCT TM, Ribeirao Preto - Brazil
Total Affiliations: 5
Document type: Journal article
Source: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY; v. 23, n. 11, p. 721-730, NOV 2020.
Web of Science Citations: 0
Abstract

Background: Our previous studies showed increased angiotensin I-converting enzyme (ACE) activity in chronic schizophrenia patients compared with healthy control (HC) volunteers, and the relevance of combining ACE genotype and activity for predicting schizophrenia was suggested. Methods: ACE activity was measured in plasma of ACE insertion/deletion (I/D) genotyped HC volunteers (n = 53) and antipsychotic-naive first-episode psychosis (FEP) patients (n = 45) assessed at baseline (FEB-B) and also after 2 months (FEP2M) of treatment with the atypical antipsychotic risperidone. Results: ACE activity measurements showed significant differences among HC, FEP-B, and FEP-2M groups (F = 5.356, df = 2, P =.005) as well as between HC and FEP-2M (post-hoc Tukey's multiple comparisons test, P =.004). No correlation was observed for ACE activity increases and symptom severity reductions in FEP as assessed by total Positive and Negative Syndrome Scale (r = -0.131, P =.434). FEP subgrouped by ACE I/D genotype showed significant ACE activity increases, mainly in the DD genotype subgroup. No correlation between ACE activity and age was observed in FEP or HC groups separately (r = 0.210, P =.392), but ACE activity level differences observed between these groups were influenced by age. Conclusions: The importance of measuring the ACE activity in blood plasma, associated with ACE I/D genotyping to support the follow-up of FEP patients, did not show correlation with general symptom amelioration in the present study. However, new insights into the influence of age and I/D genotype for ACE activity changes in FEP individuals upon treatment was demonstrated. (AU)

FAPESP's process: 17/25016-8 - INVESTIGATION OF THE TREATMENT RESPONSE OF SCHIZOPHRENIA WITH RISPERIDONE: A PHARMACOGENETICS STUDY IN A COHORT OF FIRST EPISODE OF PSYCHOSIS PATIENTS
Grantee:Síntia Iole Nogueira Belangero
Support type: Regular Research Grants
FAPESP's process: 17/02413-1 - Validation of crotamine as a biomarker and evaluation of its potential use in the therapy of human diseases
Grantee:Mirian Akemi Furuie Hayashi
Support type: Regular Research Grants
FAPESP's process: 12/08941-6 - The study of oligopeptidases in schizophrenia
Grantee:Camila Miyagui Yonamine Asanuma
Support type: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 19/09207-3 - Study of molecular and cellular mechanisms in mental disorders
Grantee:João Victor Silva Nani
Support type: Scholarships in Brazil - Doctorate